Transposagen Biopharmaceuticals, Inc., based in Lexington, KY, has announced the issuing of Patent No. 8,722,964 entitled, “Genetically Engineered or Transgenic Rats Exhibiting a Cancer Phenotype Due to a Disruption of Germline Tumor Suppressor Genes” on May 13th. The patent has terms extending through October 22, 2030.